Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences Inc (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company pioneering therapies targeting lipid-signaling pathways, including innovative approaches to cancer support care and neuropathic pain management. This page provides investors and researchers with verified updates on the company’s progress in developing novel treatments for conditions with high unmet medical needs.
Access comprehensive coverage of clinical trial milestones, regulatory developments, and strategic partnerships. Our curated news collection includes press releases about Artelo’s proprietary cocrystal technology, FABP5 inhibitor program, and advancements in cannabinoid-based therapeutics – all essential for tracking the company’s pipeline evolution.
Stay informed about critical updates including Phase trial results, intellectual property filings, and collaborations with global research institutions. Bookmark this page for real-time insights into how Artelo Biosciences is advancing treatments for chemotherapy-induced neuropathy, cancer-related anorexia, and inflammatory conditions through cutting-edge science.
Artelo Biosciences (Nasdaq: ARTL) has initiated the Phase 2a segment of its Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at treating cancer-related anorexia and weight loss. The study will assess 40 patients, using a 3:1 ratio for ART27.13 versus placebo over 12 weeks. Following positive safety outcomes in Phase 1b, a dose of 650 micrograms will be administered. About 18 clinical sites across five countries will participate. ART27.13 targets cannabinoid receptors and has shown potential for increasing appetite without adverse central nervous system effects. The global market for addressing anorexia in cancer patients is estimated over $2 billion. The company hopes to complete patient enrollment by mid-2024.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
